Rai Ajit Srivastava is currently a Senior Director of Pharmacology at Gemphire Therapeutics, Livonia, MI focusing on developing a small molecule for the treatment of cardiovascular disease and diabetes. He is also an Adjunct Professor at Food and Nutrition Department of Wayne State University, Detroit, MI. Dr Srivastava completed his education (B.Sc. Hons, MS Biochemistry and PhD from BHU, India. He obtained postdoctoral training at Washington University School of Medicine, USA and served there as a faculty for 10 years. He is an experienced leader in research and development for the past more than three decades in the metabolic, inflammatory and cardiovascular therapeutic area with demonstrated scholarship through educating students, training researchers, leading teams and advancing several NCEs and biologics to clinical development. He served in leadership positions in Tularik Pharmaceuticals (now Amgen), Bristol-Myers Squibb, and Esperion Therapeutics, USA. He has reviewed and proposed biology targets in diabetes and cardiovascular therapeutic area, investigated mechanism of action of novel compounds, and led teams to carry out preclinical discovery, pharmacology proof of concept, and pharmacokinetic/ pharmacodynamics studies. He developed and taught courses in advanced biotechnology for BS and MS students and taught and trained medical students and fellows at Washington University, St Louis. Dr Srivastava coordinated several project teams across functional areas and managed collaborative studies with academic institutions and contract research organizations. His accomplishments include submission of 5 INDs that advanced to clinic. He served as a guest Editor of special issue on Obesity for Bentham Scientific Publications, and currently an associate editor of Nutrition and Metabolism, and review editor of Frontiers in Biology. He has chaired sessions on International Scientific meetings and discussion panels, and is a member on the advisory board of biotech companies and learned societies. Has published more than 80 peer reviewed research papers, 4 book chapters, 3 patents, and more than 80 presentations in International conferences and symposia.
Srivastava’s research interests are: Cardiovascular disease, diabetes, dyslipidemia, metabolic disease and inflammatory disease.